The U.S. Senate passed a revised version of the Biosecure Act as an amendment to the FY26 National Defense Authorization Act, seeking to restrict federal contracts and funding with biotechnology firms deemed 'of concern' — a move targeting national security risks tied to foreign suppliers. The iteration omits specific company names but preserves mechanisms to limit engagement with listed entities, setting up a House‑Senate reconciliation fight and adding regulatory uncertainty for global supply chains and academic‑industry collaborations.